Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cambridge Laboratories hails success of lead product

Cambridge Laboratories hails success of lead product

18th August 2008

Cambridge Laboratories has hailed the ongoing success of its lead product Xenazine (tetrabenazine).

Xenazine is a highly-selective reversible dopamine depletor that operates by inhibiting monoamine transporter 2 and is indicated as a treatment of chorea associated with Huntington’s disease.

In a phase III study published in the Neurology journal in 2006, the compound was shown to reduce the chorea burden of Huntingdon’s patients without causing the adverse affects experienced when using unlicensed treatment regimens.

This week the compound was approved by the US Food and Drug Administration and will be distributed in that country by Prestwick Pharmaceuticals, a partner of Cambridge.

Mark Evans, chief executive of Cambridge, said: “Xenazine is Cambridge’s lead product and continues to achieve great success outside of the US.”

He added the recent FDA decision marks a major milestone for the company and underlines its robust commitment to specialist secondary care and the field of central nervous system disorders.

The company said it will work together with Prestwick to ensure the success of Xenazine as it enters the US marketplace.

In November 2007, Zenazine was launched in Italy by Cambridge’s distribution partner Chiesi Group, which followed the drug’s introduction to Germany and France.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.